0001209191-21-026823.txt : 20210415 0001209191-21-026823.hdr.sgml : 20210415 20210415161500 ACCESSION NUMBER: 0001209191-21-026823 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210413 FILED AS OF DATE: 20210415 DATE AS OF CHANGE: 20210415 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Muralidhar Bali CENTRAL INDEX KEY: 0001784138 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40315 FILM NUMBER: 21828636 MAIL ADDRESS: STREET 1: C/O EXICURE, INC. STREET 2: 8045 LAMON AVENUE, SUITE 410 CITY: SKOKIE STATE: IL ZIP: 60077 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Reneo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001637715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472309515 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: P.O. BOX 675614 CITY: RANCHO SANTA FE STATE: CA ZIP: 92067 BUSINESS PHONE: 619-733-3852 MAIL ADDRESS: STREET 1: P.O. BOX 675614 CITY: RANCHO SANTA FE STATE: CA ZIP: 92067 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-13 0 0001637715 Reneo Pharmaceuticals, Inc. RPHM 0001784138 Muralidhar Bali C/O RENEO PHARMACEUTICALS, INC. 12230 EL CAMINO REAL, SUITE 230 SAN DIEGO CA 92130 1 0 0 0 Common Stock 2021-04-13 4 C 0 1658226 A 1658226 I By Abingworth Bioventures 8 LP Common Stock 2021-04-13 4 P 0 200000 15.00 A 1858226 I By Abingworth Bioventures 8 LP Series B Preferred Stock 2021-04-13 4 C 0 7420232 0.00 D Common Stock 1658226 0 I By Abingworth Bioventures 8 LP All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. See Exhibit 99.1 The shares were purchased in the Issuer's initial public offering. /s/ Vineet R. Jindal, Attorney-in-Fact 2021-04-15 EX-99.1 2 attachment1.htm EX-99.1 DOCUMENT

Exhibit 99.1

(2) The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8").
Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8.
Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP,
the "General Partners"), serves as the general partner of Abingworth Bioventures
8 GP LP.  Abingworth 8 (acting by its general partner Abingworth Bioventures 8
GP LP, acting by its general partner Abingworth General Partner 8 LLP) has
delegated to Abingworth LLP all investment and dispositive power over the
securities held by Abingworth 8. The Reporting Person, a Director of the Issuer,
is a member of an investment committee of Abingworth 8 which approves investment
and voting decisions by majority vote and no individual member has the sole
control or voting power over the securities held by Abingworth 8. Each of
Abingworth 8, Abingworth LLP, the General Partners and each member of the
Investment Committee disclaims beneficial ownership of the common stock held by
Abingworth 8.